Pettinati H M, Volpicelli J R, Kranzler H R, Luck G, Rukstalis M R, Cnaan A
Center for the Study of Addictions, Department of Psychiatry, University of Pennsylvania School of Medicine, and the Philadelphia Veterans Affairs Medical Center, 19104-6178, USA.
Alcohol Clin Exp Res. 2000 Jul;24(7):1041-9.
Characteristic behaviors of some alcohol-dependent individuals, e.g., binge drinking, comorbid psychopathology, and some types of alcohol-related problems, have been linked to abnormalities in serotonergic neurotransmission. However, studies that have evaluated serotonergic pharmacotherapy for reducing drinking have yielded conflicting results. One explanation for these findings is a general failure to distinguish alcohol subgroups that may be differentiated on the basis of serotonergic abnormalities. However, in 1996, Kranzler and colleagues reported that Type B alcoholics, who are characterized by high levels of premorbid vulnerability, alcohol dependence severity, and comorbid psychopathology, showed less favorable drinking outcomes in response to treatment with fluoxetine, a serotonin reuptake inhibitor, than with placebo. This medication effect was not seen in Type A alcoholics, i.e., those with lower risk/severity of alcoholism and psychopathology. The aim of the present study was to explore the validity of differential responding by alcohol-dependent subtypes using the serotonin reuptake inhibitor, sertraline.
A k-means clustering procedure was applied to a sample of alcohol-dependent subjects enrolled in a 14-week, placebo-controlled trial of 200 mg/day of sertraline, classifying them into lower-risk/severity (Type A: n = 55) and higher-risk/severity (Type B: n = 45) subgroups.
A significant interaction between alcoholic subtype and medication condition was found, confirming the findings of Kranzler and colleagues that alcoholic subtypes responded differentially to serotonergic medication. Somewhat at variance with their results, however, the present study showed that the lower risk/severity (Type A) subjects had more favorable outcomes when treated with sertraline compared to placebo.
Alcoholic subtypes differentially responded to sertraline when used as a treatment to reduce alcohol drinking, with one subtype having more favorable outcomes. Subtyping alcoholics may help to resolve conflicting findings in the literature on serotonergic treatment of alcohol dependence.
一些酒精依赖个体的特征性行为,如暴饮、共病精神病理学以及某些类型的酒精相关问题,已与血清素能神经传递异常相关联。然而,评估血清素能药物疗法以减少饮酒的研究结果相互矛盾。对这些发现的一种解释是,普遍未能区分可能基于血清素能异常而有所不同的酒精亚组。然而,1996年,克兰兹勒及其同事报告称,B型酗酒者的特征是病前易感性、酒精依赖严重程度和共病精神病理学水平较高,与安慰剂相比,他们在使用血清素再摄取抑制剂氟西汀治疗时,饮酒结果较差。在A型酗酒者中未观察到这种药物效果,即那些酒精中毒和精神病理学风险/严重程度较低的人。本研究的目的是使用血清素再摄取抑制剂舍曲林探索酒精依赖亚型差异反应的有效性。
将k均值聚类程序应用于参加为期14周、每天200毫克舍曲林的安慰剂对照试验的酒精依赖受试者样本,将他们分为低风险/严重程度(A型:n = 55)和高风险/严重程度(B型:n = 45)亚组。
发现酗酒亚型与药物治疗条件之间存在显著交互作用,证实了克兰兹勒及其同事的发现,即酗酒亚型对血清素能药物有不同反应。然而,与他们的结果略有不同的是,本研究表明,低风险/严重程度(A型)受试者在使用舍曲林治疗时比使用安慰剂有更有利的结果。
酗酒亚型在使用舍曲林作为减少饮酒的治疗方法时反应不同,其中一个亚型有更有利的结果。对酗酒者进行亚型分类可能有助于解决关于血清素能治疗酒精依赖的文献中的矛盾发现。